Protocol Ledger

NCT05422911 · Phase II · RECRUITING

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Interventional Phase II clinical trial protocol NCT05422911 sponsored by Sun Pharmaceutical Industries Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-31 Enrollment: 192 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05422911
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)192 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05422911
Protocol FieldVerified Registry Value
NCT IdentifierNCT05422911
Consolidated Lead SponsorSun Pharmaceutical Industries Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment192 participants (ESTIMATED)
Registered Start Date2022-08-31
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI